An ACE inhibitor and active metabolite of moexipril
Related Products
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Moexiprilat

Item No. 38047

Technical Information
Formal Name
(3S)-2-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid
CAS Number
103775-14-0
Synonyms
  • RS 10029
Molecular Formula
C25H30N2O7
Formula Weight
Purity
≥95%
Formulation
A solid
DMSO: SolubleMethanol: Soluble
SMILES
C[C@H](N[C@H](C(O)=O)CCC1=CC=CC=C1)C(N2CC3=CC(OC)=C(OC)C=C3C[C@H]2C(O)=O)=O
InChi Code
InChI=1S/C25H30N2O7/c1-15(26-19(24(29)30)10-9-16-7-5-4-6-8-16)23(28)27-14-18-13-22(34-3)21(33-2)12-17(18)11-20(27)25(31)32/h4-8,12-13,15,19-20,26H,9-11,14H2,1-3H3,(H,29,30)(H,31,32)/t15-,19-,20-/m0/s1
InChi Key
CMPAGYDKASJORH-YSSFQJQWSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Moexiprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC50 = 2.1 nM) and an active metabolite of the prodrug moexipril (Item No. 21255).1 It is formed from moexipril in vivo by side chain ester hydrolysis.2 Moexiprilat (10 nM) prevents the estrone- or angiotensin II-stimulated proliferation of primary neonatal rat cardiac fibroblasts.3 It reduces mean arterial blood pressure and increases the levels of atrial natriuretic peptide, a marker of hypertension, in ovariectomized mice when administered at a dose of 50 mg/kg per day.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Edling, O., Bao, G., Feelisch, M., et alMoexipril, a new angiotensin-converting enzyme (ACE) inhibitor: Pharmacological characterization and comparison with enalapril. J. Pharmacol. Exp. Ther. 275(2), 854-863 (1995).

    2. Cameron, R.T., Coleman, R.G., Day, J.P., et alChemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). Biochem. Pharmacol. 85(9), 1297-1305 (2013).

    3. Grohé, C., Kahlert, S., Löbber, K., et alAngiotensin converting enzyme inhibition modulates cardiac fibroblast growth. J. Hypertens. 16(3), 377-384 (1998).

    4. van Eickels, M., Schreckenberg, R., Doevendans, P.A., et alThe influence of oestrogen-deficiency and ACE inhibition on the progression of myocardial hypertrophy in spontaneously hypertensive rats. Eur. J. Heart Fail. 7(7), 1079-1084 (2005).